# Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)

> **NCT00230971** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 473 (actual)

## Conditions studied

- Appendicitis
- Cholecystitis
- Diverticulitis
- Intra-Abdominal Abscess
- Intra-Abdominal Infection
- Peritonitis

## Interventions

- **DRUG:** tigecycline
- **DRUG:** ceftriaxone plus metronidazole

## Key facts

- **NCT ID:** NCT00230971
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 473 (ACTUAL)
- **Last updated:** 2013-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230971, "Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00230971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*